Review
Chemistry, Inorganic & Nuclear
Brian J. Goodfellow, Filipe Freire, Ana Luisa Carvalho, Susana S. Aveiro, Peggy Charbonnier, Jean-Marc Moulis, Leonildo Delgado, Gloria C. Ferreira, Joao E. Rodrigues, Pierre Poussin-Courmontagne, Catherine Birck, Alastair McEwen, Anjos L. Macedo
Summary: The SOUL family represents a group of evolutionary conserved putative heme-binding proteins found in animal, plant, and bacterial species. The interaction between tetrapyrroles and HEBP1 was initially thought to involve hydrophobic and electrostatic interactions, but new data confirms the hydrophobic nature of the heme-HEBP1 interaction. The structures of HEBP1 and HEBP2 differ, with HEBP1 maintaining a rigid structure upon heme binding while HEBP2 does not interact with heme at all.
COORDINATION CHEMISTRY REVIEWS
(2021)
Review
Hematology
Andrew W. Roberts, Andrew H. Wei, David C. S. Huang
Summary: BH3 mimetics are a new class of anticancer drugs that target prosurvival BCL2 proteins to induce apoptosis, with Venetoclax being the first approved BCL2 inhibitor showing activity in various lymphoid and myeloid neoplasms. Long-term exposure may lead to secondary resistance. Success of BCL2 inhibitors has led to development of BH3 mimetics targeting MCL1, with promising preclinical activity but potential challenges due to MCL1's physiological roles in nonhematologic tissues.
Review
Biochemistry & Molecular Biology
R. Franca, S. Braidotti, G. Stocco, G. Decorti
Summary: To safely and effectively titrate thiopurines, a combination of preemptive TPMT genotyping and close phenotypic monitoring of TPMT activity is necessary. Investigating individualized TG regimens could improve outcomes while avoiding severe hepatotoxicity in ALL patients.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2021)
Article
Oncology
Qianling Ye, Yun Lin, Ruihao Li, Huaiji Wang, Chunyan Dong
Summary: This article introduces the unique advantages of nanodrug delivery systems in the treatment of hematological malignancies, focusing on the factors involved in tailoring nanoparticles and different types of nanomaterials. It reviews the recent advances in nanodrug delivery systems for HM treatment and discusses the challenges and prospects they face.
SEMINARS IN CANCER BIOLOGY
(2022)
Article
Immunology
Zilong Guo, Yirui Zhang, Mingpeng Fu, Liang Zhao, Zhen Wang, Zhuoshuo Xu, Huifen Zhu, Xiaoli Lan, Guanxin Shen, Yong He, Ping Lei
Summary: The transferrin receptor (TfR) is being evaluated as an alternative target for CAR T cell therapy, showing potent cytotoxic effects against hematological malignancies. This suggests TfR could potentially broaden and enhance the therapeutic efficacy of CAR T cells, making it a promising universal target for further research.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Hematology
Yassmine M. N. Akkari, Linda B. Baughn, Adrian M. Dubuc, Adam C. Smith, Mar Mallo, Paola Dal Cin, Maria Diez Campelo, Marta S. Gallego, Isabel Granada Font, Detlef T. Haase, Brigitte Schlegelberger, Irma Slavutsky, Cristina Mecucci, Ross L. Levine, Robert P. Hasserjian, Francesc Sole, Brynn Levy, Xinjie Xu
Summary: Cytogenetics is crucial in the clinical evaluation of hematologic malignancies. Chromosome banding studies and novel sequencing technologies have advantages and limitations, and their implementation in the global clinical setting requires consideration of clinical, logistic, technical, and financial factors.
Article
Oncology
Nan Zhang, Jinxian Wu, Qian Wang, Yuxing Liang, Xinqi Li, Guopeng Chen, Linlu Ma, Xiaoyan Liu, Fuling Zhou
Summary: Hematologic malignancies are common cancers and understanding their incidence and death rates is crucial. The study examined data from 1990 to 2019 and found that globally, incident cases of hematologic malignancies have been increasing while the death rates have been declining. However, there are variations in trends based on gender, age, region, and economic situation.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Yangping Wu, Jingliao Zhang, Xiaofan Zhu, Yingchi Zhang
Summary: PROTACs, as a novel drug development approach, degrade target proteins via the ubiquitin-proteasome system, showing clinical potential in the treatment of hematologic malignancies. Despite their numerous advantages, PROTACs face challenges in design, synthesis, evaluation, and clinical application.
Article
Oncology
Mark A. Dawson, Gautam Borthakur, Brian J. P. Huntly, Anastasios Karadimitris, Adrian Alegre, Aristeidis Chaidos, Dan T. Vogl, Daniel A. Pollyea, Faith E. Davies, Gareth J. Morgan, Jacob L. Glass, Manali Kamdar, Maria -Victoria Mateos, Natalia Tovar, Paul Yeh, Regina Garcia Delgado, Faisal Basheer, Ludovica Marando, Paolo Gallipoli, Anastasia Wyce, Anu Shilpa Krishnatry, Olena Barbash, Evi Bakirtzi, Geraldine Ferron-Brady, Natalie O. Karpinich, Michael T. McCabe, Shawn W. Foley, Thierry Horner, Arindam Dhar, Brandon E. Kremer, Michael Dickinson
Summary: Molibresib, a selective inhibitor of BET proteins, was evaluated as a monotherapy for hematological malignancies. The study consisted of dose escalation to determine the recommended dose and dose expansion to assess safety and efficacy in relapsed/refractory MDS and CTCL patients. Results showed limited antitumor activity and significant toxicities, suggesting the need for combination regimens with molibresib.
CLINICAL CANCER RESEARCH
(2023)
Review
Oncology
Jia Xu, Wenjing Luo, Chenggong Li, Heng Mei
Summary: CD19-targeted CAR-T cell therapy has shown remarkable efficacy in treating B-cell malignancies, but CD19-negative relapse remains a significant challenge. CD22 serves as a potential alternative target for CD19 CAR-T cell-resistant patients, with therapies showing acceptable toxicities and promising efficacy.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Review
Immunology
Paola Sindaco, Hritisha Pandey, Colleen Isabelle, Nitin Chakravarti, Jonathan Edward Brammer, Pierluigi Porcu, Anjali Mishra
Summary: Cytokines play a crucial role in regulating blood cell activation and growth in the immune system. However, excessive production of cytokines can lead to malignant transformation. This review focuses on the impact of interleukin-15 (IL-15) on the development and progression of hematological malignancies, discussing its role in cell survival, proliferation, inflammation, and treatment resistance. Therapeutic approaches for inhibiting IL-15 in blood cancers will also be reviewed.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Hematology
Chaja F. Jacobs, Eric Eldering, Arnon P. Kater
Summary: Tyrosine kinase inhibitors are being explored for use in the treatment of different stages of COVID-19 and other hematologic malignancies, although most studies are done in vitro and may not apply to a wider population. Many in vivo effects reported are based on artificial animal models or symptomatic patients with hematologic malignancies.
Review
Oncology
Yongkang Liao, Shijun Xiong, Zaid Ur Rehman, Xiaoli He, Hongling Peng, Jing Liu, Shuming Sun
Summary: This review summarizes the research progress of aptamers in the diagnosis and treatment of hematologic malignancies, providing support for the application of aptamers in this field. Aptamer-based targeted therapies have shown promising potential in achieving more targeted goals in hematologic malignancies. The findings of these studies provide multiple approaches for future basic and clinical trials research in this field.
Article
Hematology
Sarah J. Nagle, Catherine Murphree, Philipp W. Raess, Levanto Schachter, Andy Chen, Brandon Hayes-Lattin, Eneida Nemecek, Richard T. Maziarz
Summary: CAR T-cell therapy is effective in treating patients with R/R DLBCL, but it is associated with significant prolonged hematologic toxicity (PHT) that can affect patients' survival rates. Risk factors associated with PHT include CRS, the use of tocilizumab or steroids, peak levels of ferritin and C-reactive protein. More research is needed to further investigate PHT and establish management standards.
AMERICAN JOURNAL OF HEMATOLOGY
(2021)
Review
Chemistry, Medicinal
Feng Huang, Tian Tian, Yizhe Wu, Jinxin Che, Haiyan Yang, Xiaowu Dong
Summary: This review discusses the role of IDH2 in blood cancer, its involvement in metabolic activity of cancer cells, and the progress in identifying IDH2 inhibitors in the treatment of blood tumors, providing a reference for ongoing and future clinical studies.
MINI-REVIEWS IN MEDICINAL CHEMISTRY
(2021)
Review
Biotechnology & Applied Microbiology
Pawel Robak, Tadeusz Robak
Summary: In recent years, there have been significant advancements in the treatment of chronic lymphocytic leukemia (CLL), including the use of novel targeted drugs and monoclonal antibodies. Combination therapies with different agents have shown high activity in both treatment naive and relapsed/refractory CLL patients. However, more research is needed to determine the optimal sequencing of therapies and selection of upfront treatment options.
EXPERT OPINION ON BIOLOGICAL THERAPY
(2023)
Review
Pharmacology & Pharmacy
Aleksandra Golos, Joanna Gora-Tybor, Tadeusz Robak
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Article
Biochemistry & Molecular Biology
Anna Pula, Pawel Robak, Dariusz Jarych, Damian Mikulski, Malgorzata Misiewicz, Izabela Drozdz, Wojciech Fendler, Janusz Szemraj, Tadeusz Robak
Summary: This study aimed to analyze the expression of selected miRNAs in the serum of MM patients treated with bortezomib-based regimens and determine their ability to predict early mortality. Two miRNAs, hsa-miR-328-3p and hsa-miR-409-3p, were significantly downregulated in the early mortality group. Logistic regression analysis showed that the final model, including these miRNAs, age, and R-ISS 3, had high sensitivity and specificity in predicting early mortality.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Peter Hillmen, Barbara Eichhorst, Jennifer R. Brown, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kazmierczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda Gillespie-Twardy, Mazyar Shadman, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Tommi Salmi, Meng Ji, Jessica Yecies, Adam Idoine, Kenneth Wu, Jane Huang, Wojciech Jurczak
Summary: The study compared the efficacy and safety of zanubrutinib and ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. The results showed that zanubrutinib had better outcomes in terms of efficacy, atrial fibrillation rate, and cardiac safety compared to ibrutinib.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Dominik Dytfeld, Tomasz Wrobel, Krzysztof Jamroziak, Tadeusz Kubicki, Pawel Robak, Adam Walter-Croneck, Jaroslaw Czyz, Agata Tyczynska, Agnieszka Druzd-Sitek, Krzysztof Giannopoulos, Adam Nowicki, Tomasz Szczepaniak, Anna Lojko-Dankowska, Magdalena Matuszak, Lidia Gil, Bartosz Pula, Justyna Rybka, Maciej Majcherek, Lidia Usnarska-Zubkiewicz, Lukasz Szukalski, Agnieszka Konska, Jan Maciej Zaucha, Jan Walewski, Damian Mikulski, Olga Czabak, Tadeusz Robak, Oscar B. Lahoud, Jeffrey A. Zonder, Kent Griffith, Andrew Stefka, Ajay Major, Benjamin A. Derman, Andrzej J. Jakubowiak
Summary: This study compared the efficacy and safety of maintenance therapy with carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone in patients with newly diagnosed multiple myeloma. The results showed that the combination therapy group had longer progression-free survival compared to the lenalidomide monotherapy group. Further research is needed to confirm these findings.
Review
Pharmacology & Pharmacy
Tadeusz Robak, Pawel Robak
Summary: This article summarizes recent achievements in the treatment of relapsed and refractory hairy cell leukemia. The growing understanding of HCL biology has led to the development of several new targeted drugs, which have shown promising efficacy in early clinical trials.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2023)
Letter
Oncology
Tadeusz Robak, Jaroslaw D. Kasprzak, Dorota Jesionek-Kupnicka, Michal Soin, Pawel Robak
LEUKEMIA & LYMPHOMA
(2023)
Editorial Material
Oncology
Tadeusz Robak
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Pierre Fenaux, Marco Gobbi, Patricia L. Kropf, Jean-Pierre J. Issa, Gail J. Roboz, Jiri Mayer, Juergen Krauter, Tadeusz Robak, Hagop Kantarjian, Jan Novak, Wieslaw. W. Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph Brandwein, Liana Gercheva-Kyuchukova, Judit Demeter, Elizabeth Griffiths, Karen Yee, Konstanze Doehner, Yong Hao, Harold Keer, Mohammad Azab, Hartmut Doehner
Summary: This phase 3 study compared the efficacy and safety of the hypomethylating agent guadecitabine with other treatment choices in patients with acute myeloid leukemia unfit for intensive induction chemotherapy. The study found no significant difference in complete remission and overall survival between guadecitabine and the alternative treatments.
Review
Biochemistry & Molecular Biology
Magdalena Witkowska, Agata Majchrzak, Pawel Robak, Anna Wolska-Washer, Tadeusz Robak
Summary: PI3K & delta; inhibitors are novel agents used to treat B-cell malignancies by inhibiting enzymes in the PI3K/AKT/mTOR pathway. Idelalisib is an effective inhibitor for B-cell lymphoid malignancies.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY
(2023)
Review
Oncology
Tadeusz Robak, Anna Krawczynska, Barbara Cebula-Obrzut, Marta Urbaniak, Elzbieta Iskierka-Jazdzewska, Pawel Robak
Summary: Differentiation of leukemic cells in CLL is significant, with dissimilarities in morphology, cytogenetics, and immunophenotype. Atypical CLL differs from typical CLL morphologically and immunophenotypically, with more aggressive clinical behavior and worse prognosis. However, there is no standard criteria for differentiating atypical CLL from typical CLL and its clinical significance is still under debate.